Small cell carcinoma of the lung historical perspective: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 17: Line 17:
*1962: Watson and Berg described the specificity of SCLC in matters of origin, clinical presentation, natural history, and response to treatment, and rejected the notion that SCLC should  be included with other subtypes of lung cancer.<ref name="pmid14005321">{{cite journal| author=WATSON WL, BERG JW| title=Oat cell lung cancer. | journal=Cancer | year= 1962 | volume= 15 | issue=  | pages= 759-68 | pmid=14005321 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14005321  }} </ref>
*1962: Watson and Berg described the specificity of SCLC in matters of origin, clinical presentation, natural history, and response to treatment, and rejected the notion that SCLC should  be included with other subtypes of lung cancer.<ref name="pmid14005321">{{cite journal| author=WATSON WL, BERG JW| title=Oat cell lung cancer. | journal=Cancer | year= 1962 | volume= 15 | issue=  | pages= 759-68 | pmid=14005321 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14005321  }} </ref>
*1969: Green et al demonstrated a statistically significant survival benefit of cyclophosphamide in lung cancer patients.<ref name="pmid5791000">{{cite journal| author=Green RA, Humphrey E, Close H, Patno ME| title=Alkylating agents in bronchogenic carcinoma. | journal=Am J Med | year= 1969 | volume= 46 | issue= 4 | pages= 516-25 | pmid=5791000 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=5791000  }} </ref>
*1969: Green et al demonstrated a statistically significant survival benefit of cyclophosphamide in lung cancer patients.<ref name="pmid5791000">{{cite journal| author=Green RA, Humphrey E, Close H, Patno ME| title=Alkylating agents in bronchogenic carcinoma. | journal=Am J Med | year= 1969 | volume= 46 | issue= 4 | pages= 516-25 | pmid=5791000 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=5791000  }} </ref>
*1970s: It was observed that combination therapy is superior compared with single-agent therapy.<ref name="pmid224997">{{cite journal| author=Lowenbraun S, Bartolucci A, Smalley RV, Lynn M, Krauss S, Durant JR| title=The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. | journal=Cancer | year= 1979 | volume= 44 | issue= 2 | pages= 406-13 | pmid=224997 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=224997  }} </ref>
*1980s: Regimens built around etoposide become the treatment of choice.<ref name="pmid3020700">{{cite journal| author=Bunn PA, Greco FA, Einhorn L| title=Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer. | journal=Semin Oncol | year= 1986 | volume= 13 | issue= 3 Suppl 3 | pages= 45-53 | pmid=3020700 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3020700  }} </ref>
*1981: The WHO classified SCLC into three subtypes: (1) oat cell carcinoma (2) intermediate cell type, and (3) combined oat cell carcinoma.<ref name="pmid7064914">{{cite journal| author=| title=The World Health Organization histological typing of lung tumours. Second edition. | journal=Am J Clin Pathol | year= 1982 | volume= 77 | issue= 2 | pages= 123-36 | pmid=7064914 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7064914  }} </ref>
*1981: The WHO classified SCLC into three subtypes: (1) oat cell carcinoma (2) intermediate cell type, and (3) combined oat cell carcinoma.<ref name="pmid7064914">{{cite journal| author=| title=The World Health Organization histological typing of lung tumours. Second edition. | journal=Am J Clin Pathol | year= 1982 | volume= 77 | issue= 2 | pages= 123-36 | pmid=7064914 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7064914  }} </ref>
*1988: The International Association for the Study of Lung Cancer (IASLC) proposed that the intermediate cell type category be eliminated. and a new category, "mixed" small/large-cell carcinoma, was added.<ref name="pmid2842029">{{cite journal| author=Hirsch FR, Matthews MJ, Aisner S, Campobasso O, Elema JD, Gazdar AF et al.| title=Histopathologic classification of small cell lung cancer. Changing concepts and terminology. | journal=Cancer | year= 1988 | volume= 62 | issue= 5 | pages= 973-7 | pmid=2842029 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2842029  }} </ref> But, because there were problems in reproductibility of all these subtypes, combined SCLC is the only subtype in the new WHO/IASLC classification.<ref name="pmid10929757">{{cite journal| author=Junker K, Wiethege T, Müller KM| title=Pathology of small-cell lung cancer. | journal=J Cancer Res Clin Oncol | year= 2000 | volume= 126 | issue= 7 | pages= 361-8 | pmid=10929757 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10929757  }} </ref>
*1988: The International Association for the Study of Lung Cancer (IASLC) proposed that the intermediate cell type category be eliminated. and a new category, "mixed" small/large-cell carcinoma, was added.<ref name="pmid2842029">{{cite journal| author=Hirsch FR, Matthews MJ, Aisner S, Campobasso O, Elema JD, Gazdar AF et al.| title=Histopathologic classification of small cell lung cancer. Changing concepts and terminology. | journal=Cancer | year= 1988 | volume= 62 | issue= 5 | pages= 973-7 | pmid=2842029 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2842029  }} </ref> But, because there were problems in reproductibility of all these subtypes, combined SCLC is the only subtype in the new WHO/IASLC classification.<ref name="pmid10929757">{{cite journal| author=Junker K, Wiethege T, Müller KM| title=Pathology of small-cell lung cancer. | journal=J Cancer Res Clin Oncol | year= 2000 | volume= 126 | issue= 7 | pages= 361-8 | pmid=10929757 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10929757  }} </ref>

Revision as of 16:20, 9 June 2014

Small Cell Carcinoma of the Lung Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Small Cell Carcinoma of the Lung from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Radiation Therapy

Surgery

Prevention

Future or Investigational Therapies

Case Studies

Case #1

Small cell carcinoma of the lung historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Small cell carcinoma of the lung historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Small cell carcinoma of the lung historical perspective

CDC on Small cell carcinoma of the lung historical perspective

Small cell carcinoma of the lung historical perspective in the news

Blogs on Small cell carcinoma of the lung historical perspective

Directions to Hospitals Treating Small cell carcinoma of the lung

Risk calculators and risk factors for Small cell carcinoma of the lung historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-in-Chief: Guillermo Rodriguez Nava, M.D. [2]

Overview

Laennec first recognized lung cancer as a separate disease in 1815, in his work "Encephaloides" published in the Dictionnaire des sciences médicales.[1] Azzopardi, in 1959, distinguished small cell lung cancer (SCLC) from anaplastic adenocarcinoma and squamous cell carcinoma and described the historical, cytologic and histochemical features that characterize it as a separate disease.[2]

Historical Perspective

Important landmarks in the history of small cell carcinoma of the lung include the following:

  • 1492: Christopher Columbus received tobacco as a gift, among other things, from the Native Americans.[1]
  • 1500s: Tobacco reached Europe and its use spreads.[1]
  • 1815: Laennec recognized lung cancer as a separate disease.[1]
  • 1926: Barnard observed that "oat-celled sarcomas of the mediastinum" were indeed lung neoplasms.[3]
  • 1950: Doll and Hill described an association between smoking and lung cancer.[4]
  • 1959-1962: SCLC was recognized as separate from other types of lung cancers. Azzopardi described it microscopically and named six characteristic features of it.[2] The term "small cell carcinoma" began to become more popular between American authors, while Europeans continued to call it "oat cell carcinoma", because of the resemblance to oat grains.[3]
  • 1962: Watson and Berg described the specificity of SCLC in matters of origin, clinical presentation, natural history, and response to treatment, and rejected the notion that SCLC should be included with other subtypes of lung cancer.[5]
  • 1969: Green et al demonstrated a statistically significant survival benefit of cyclophosphamide in lung cancer patients.[6]
  • 1970s: It was observed that combination therapy is superior compared with single-agent therapy.[7]
  • 1980s: Regimens built around etoposide become the treatment of choice.[8]
  • 1981: The WHO classified SCLC into three subtypes: (1) oat cell carcinoma (2) intermediate cell type, and (3) combined oat cell carcinoma.[9]
  • 1988: The International Association for the Study of Lung Cancer (IASLC) proposed that the intermediate cell type category be eliminated. and a new category, "mixed" small/large-cell carcinoma, was added.[10] But, because there were problems in reproductibility of all these subtypes, combined SCLC is the only subtype in the new WHO/IASLC classification.[11]

References

  1. ↑ 1.0 1.1 1.2 1.3 ROSENBLATT MB (1964). "LUNG CANCER IN THE 19TH CENTURY". Bull Hist Med. 38: 395–425. PMID 14213122.
  2. ↑ 2.0 2.1 AZZOPARDI JG (1959). "Oat-cell carcinoma of the bronchus". J Pathol Bacteriol. 78: 513–9. PMID 13795444.
  3. ↑ 3.0 3.1 Barnard, W. G. (1926). "The nature of the "oat-celled sarcoma" of the mediastinum". The Journal of Pathology and Bacteriology. 29 (3): 241–244. doi:10.1002/path.1700290304. ISSN 0368-3494.
  4. ↑ DOLL R, HILL AB (1950). "Smoking and carcinoma of the lung; preliminary report". Br Med J. 2 (4682): 739–48. PMC 2038856. PMID 14772469.
  5. ↑ WATSON WL, BERG JW (1962). "Oat cell lung cancer". Cancer. 15: 759–68. PMID 14005321.
  6. ↑ Green RA, Humphrey E, Close H, Patno ME (1969). "Alkylating agents in bronchogenic carcinoma". Am J Med. 46 (4): 516–25. PMID 5791000.
  7. ↑ Lowenbraun S, Bartolucci A, Smalley RV, Lynn M, Krauss S, Durant JR (1979). "The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma". Cancer. 44 (2): 406–13. PMID 224997.
  8. ↑ Bunn PA, Greco FA, Einhorn L (1986). "Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer". Semin Oncol. 13 (3 Suppl 3): 45–53. PMID 3020700.
  9. ↑ "The World Health Organization histological typing of lung tumours. Second edition". Am J Clin Pathol. 77 (2): 123–36. 1982. PMID 7064914.
  10. ↑ Hirsch FR, Matthews MJ, Aisner S, Campobasso O, Elema JD, Gazdar AF; et al. (1988). "Histopathologic classification of small cell lung cancer. Changing concepts and terminology". Cancer. 62 (5): 973–7. PMID 2842029.
  11. ↑ Junker K, Wiethege T, Müller KM (2000). "Pathology of small-cell lung cancer". J Cancer Res Clin Oncol. 126 (7): 361–8. PMID 10929757.


Retrieved from "https://www.wikidoc.org/index.php?title=Small_cell_carcinoma_of_the_lung_historical_perspective&oldid=976677"